CAR Ts Kymriah, Yescarta get green light in EU

The European Commission approved Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN) and Yescarta axicabtagene ciloleucel from the Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD), making them the first approved CAR T therapies in the EU.

Kymriah is indicated to treat pediatric and young adult patients up to 25 years of age with B cell acute lymphoblastic leukemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse, and to treat adults with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy...